Tyrphostin A9 通过抑制 PYK2/EGFR-ERK 信号通路减弱胶质母细胞瘤生长
研究分析 48 例星形细胞瘤活检标本及 GBM 细胞系中 PYK2 与 EGFR 的表达及临床关联,并在体外和颅内 C6 胶质瘤模型中评估 Tyrphostin A9 的抗癌效果。结果显示磷酸化 PYK2 和 EGFR 表达升高与星形细胞瘤恶性程度加重及患者生存不良相关,Tyrphostin A9 通过抑制 PYK2/EGFR-ERK 信号通路减少 GBM 细胞生长、迁移并诱导凋亡,在体内缩小胶质瘤生长并延长动物生存。
要点
- 星形细胞瘤中磷酸化 PYK2 和 EGFR 表达升高与恶性程度加重及患者生存不良相关。
- GBM 组织中磷酸化 PYK2 与 EGFR 的 mRNA 和蛋白表达呈正相关。
- Tyrphostin A9 在体外减少 GBM 细胞生长和迁移并诱导凋亡,在体内缩小胶质瘤并延长动物生存。
核心结论
- 星形细胞瘤中磷酸化 PYK2 和 EGFR 表达升高与不良预后相关。
- 体外和体内证据支持 Tyrphostin A9 通过抑制 PYK2/EGFR-ERK 信号通路具有转化意义。
研究设计与样本
- 研究评估 48 例星形细胞瘤活检标本和 GBM 细胞系中 PYK2 与 EGFR 的表达谱。
- 采用定量 PCR、蛋白质印迹和免疫组化检测表达,并用 Kaplan-Meier 生存曲线分析临床关联。
- 在 GBM 细胞系和颅内 C6 胶质瘤模型中评估 Tyrphostin A9 的可成药性及抗癌效果。
主要发现
- 磷酸化 PYK2 和 EGFR 表达升高加重星形细胞瘤恶性程度并与患者生存不良相关。
- GBM 组织中磷酸化 PYK2 与 EGFR 的 mRNA 和蛋白表达呈正相关。
- 体外实验中 Tyrphostin A9 通过减弱 PYK2/EGFR-ERK 信号降低 GBM 细胞生长和迁移并诱导凋亡。
- 体内实验中 Tyrphostin A9 治疗通过抑制 PYK2/EGFR-ERK 信号显著减少胶质瘤生长并延长动物生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Glioblastoma (GBM) is a fatal primary brain tumor with extremely poor clinical outcomes. The anticancer efficiency of tyrosine kinase inhibitors (TKIs) has been shown in GBM and other cancer, with limited therapeutic outcomes. In the current study, we aimed to investigate the clinical impact of active proline-rich tyrosine kinase-2 (PYK2) and epidermal growth factor receptor (EGFR) in GBM and evaluate its druggability by a synthetic TKI-Tyrphostin A9 (TYR A9). METHODS: The expression profile of PYK2 and EGFR in astrocytoma biopsies (n = 48) and GBM cell lines were evaluated through quantitative PCR, western blots, and immunohistochemistry. The clinical association of phospho-PYK2 and EGFR was analyzed with various clinicopathological features and the Kaplan-Meier survival curve. The phospho-PYK2 and EGFR druggability and subsequent anticancer efficacy of TYR A9 was evaluated in GBM cell lines and intracranial C6 glioma model. RESULTS: Our expression data revealed an increased phospho-PYK2, and EGFR expression aggravates astrocytoma malignancy and is associated with patients' poor survival. The mRNA and protein correlation analysis showed a positive association between phospho-PYK2 and EGFR in GBM tissues. The in-vitro studies demonstrated that TYR A9 reduced GBM cell growth, cell migration, and induced apoptosis by attenuating PYK2/EGFR-ERK signaling. The in-vivo data showed TYR A9 treatment dramatically reduced glioma growth with augmented animal survival by repressing PYK2/EGFR-ERK signaling. CONCLUSION: Altogether, this study report that increased phospho-PYK2 and EGFR expression in astrocytoma was associated with poor prognosis. The in-vitro and in-vivo evidence underlined translational implication of TYR A9 by suppressing PYK2/EGFR-ERK modulated signaling pathway. The schematic diagram displayed proof of concept of the current study indicating activated PYK2 either through the Ca2+/Calmodulin-dependent protein kinase II (CAMKII) signaling pathway or autophosphorylation at Tyr402 induces association to the SH2 domain of c-Src that leads to c-Src activation. Activated c-Src in turn activates PYK2 at other tyrosine residues that recruit Grb2/SOS complex and trigger ERK½ activation. Besides, PYK2 interaction with c-Src acts as an upstream of EGFR transactivator that can activate the ERK½ signaling pathway, which induces cell proliferation and cell survival by increasing anti-apoptotic proteins or inhibiting pro-apoptotic proteins. TYR A9 treatment attenuate GBM cell proliferation and migration; and induce GBM cell death by inhibiting PYK2 and EGFR-induced ERK activation.
引用
- Yadav N, Babu D, Madigubba S, et al. Tyrphostin A9 attenuates glioblastoma growth by suppressing PYK2/EGFR-ERK signaling pathway. J Neurooncol. 2023. PMID: 37415005. doi:10.1007/s11060-023-04383-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。